Equities analysts expect that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will report sales of $2.09 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The lowest sales estimate is $1.50 million and the highest is $3.31 million. Tetraphase Pharmaceuticals posted sales of $4.07 million during the same quarter last year, which suggests a negative year over year growth rate of 48.6%. The company is scheduled to report its next earnings report on Thursday, November 1st.
On average, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $16.68 million for the current year, with estimates ranging from $8.00 million to $21.28 million. For the next year, analysts anticipate that the business will report sales of $22.61 million per share, with estimates ranging from $12.00 million to $46.03 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.18. The business had revenue of $11.58 million during the quarter, compared to analysts’ expectations of $2.23 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%.
Large investors have recently added to or reduced their stakes in the stock. Flagship Harbor Advisors LLC purchased a new stake in shares of Tetraphase Pharmaceuticals during the second quarter worth about $104,000. Cubist Systematic Strategies LLC grew its position in shares of Tetraphase Pharmaceuticals by 232.1% during the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 24,837 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Tetraphase Pharmaceuticals during the second quarter worth about $179,000. Dynamic Technology Lab Private Ltd grew its position in shares of Tetraphase Pharmaceuticals by 322.1% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 58,079 shares in the last quarter. Finally, Alambic Investment Management L.P. purchased a new stake in shares of Tetraphase Pharmaceuticals during the first quarter worth about $356,000. Hedge funds and other institutional investors own 40.94% of the company’s stock.
TTPH traded down $0.07 during midday trading on Friday, reaching $3.07. The company had a trading volume of 439,103 shares, compared to its average volume of 1,261,593. Tetraphase Pharmaceuticals has a 1 year low of $2.05 and a 1 year high of $7.98.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Further Reading: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.